Why Biohaven Catapulted 30%-Plus — And Why It Might Not Be Done Sprinting

Biohaven stock catapulted more than 30% early Thursday after the FDA said it would review the company's embattled drug, troriluzole. The post Why Biohaven Catapulted 30%-Plus — And Why It Might Not Be Done Sprinting appeared first on Investor's Business Daily.